SynapDx

NEW YORK (GenomeWeb News) – SynapDx today announced a collaboration with the Broad Institute to develop next-generation sequencing analysis methods to improve autism diagnostics.

NEW YORK (GenomeWeb News) – The Massachusetts Life Sciences Center has released the list of firms that will receive a total of $25 million in tax incentives tied to job creation this year, and that list includes several omics and molecular diagnostics firms.

Paired Ends: Kevin Hrusovsky

Premium

SynapDx has appointed Kevin Hrusovsky to the firm's board of directors. He most recently served as president of life sciences and technology at PerkinElmer.

SynapDx said this week that Mark DePristo has joined the Lexington, Mass.-based company as vice pres

Illumina has appointed Richard Klausner to senior vice president and Chief Medical Officer, where he will lead Illumina's strategies for advancing genomics into clinical medicine and public health.

Illumina has appointed Richard Klausner to senior vice president and Chief Medical Officer, where he will lead Illumina's strategies for advancing genomics into clinical medicine and public health.

Companies that sell or are developing microarray-based tests for early stage autism diagnosis will soon face off against a competitor with a next-generation sequencing-based offering.

SynapDx this week appointed Andrew Conrad to the company's board of directors.

NEW YORK (GenomeWeb News) – Autism diagnostics firm SynapDx today said that it raised $15.4 million.

NEW YORK (GenomeWeb News) – SynapDx this week said that it has received a "significant investment" from The Kraft Group that will support ongoing clinical development of its molecular diagnostic test for autism spectrum disorder.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.